Pharmacogenomic Information on Vemurafenib

Pharmacogenomic Information

DrugTherapeutic Area*
Labeling Sections
VemurafenibOncologyBRAFBRAF V600E
mutation positive
Indications and Usage, Dosage and Administration,
Warning and Precautions, Clinical Pharmacology,
Clinical Studies, Patient Counseling Information


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 02/22/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.